Sofinnova Crossover I 13D and 13G filings for MaxCyte, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-13 2:08 pm Sale | 2022-12-31 | 13G | MaxCyte, Inc. MXCT | Sofinnova Crossover I | 4,610,693 4.500% | -500,000 (-9.78%) | Filing |
| 2022-02-11 10:59 am Purchase | 2021-12-31 | 13G | MaxCyte, Inc. MXCT | Sofinnova Crossover I | 5,110,693 5.100% | 5,110,693 (New Position) | Filing |